Niagen Bioscience, Inc.
NAGE
$6.76
$0.223.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 282.27% | 12,620.00% | 96.95% | -531.58% | 111.89% |
| Total Depreciation and Amortization | -2.19% | -1.08% | -5.13% | 4.56% | -16.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -643.45% | -38.59% | 17.12% | -3.17% | -19.19% |
| Change in Net Operating Assets | 916.10% | 127.38% | -185.69% | 29.50% | -116.11% |
| Cash from Operations | 145.58% | 1,423.86% | -189.49% | -54.55% | 63.89% |
| Capital Expenditure | -68.29% | -241.67% | 70.73% | -95.24% | 19.23% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -228.57% | -75.00% | 70.73% | -95.24% | 19.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 50.00% | -100.00% | 33.33% | -200.00% | 66.67% |
| Issuance of Common Stock | 263.47% | 74.41% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 85.33% | -- |
| Cash from Financing | 260.73% | 74.33% | 4,357.14% | 81.58% | -2,433.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 171.70% | 1,310.31% | 33.33% | -56.52% | 50.41% |